🇰🇷 South Korea Country × Condition
bladder cancer Clinical Trials in South Korea
Active clinical trials for bladder cancer with research sites in South Korea. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇰🇷 South Korea
Active Trials in South Korea (2)
NCT07232602 Phase 1, Phase 2
Recruiting
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Enrollment
55 pts
Country
🇰🇷 South Korea
Merck Sharp & Dohme LLC
View Trial → NCT04197414
Recruiting
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Enrollment
3,000 pts
Country
🇰🇷 South Korea
Yonsei University
View Trial → Frequently Asked Questions
How many bladder cancer clinical trials are active in South Korea?
There are currently 2 active clinical trials for bladder cancer with sites in South Korea, of which 2 are actively recruiting patients.
How can I join a bladder cancer clinical trial in South Korea?
To join a bladder cancer clinical trial in South Korea, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in South Korea directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are bladder cancer trials in South Korea?
Active bladder cancer trials in South Korea span Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology